Comparative Pharmacology
Head-to-head clinical analysis: MENTAX versus PENLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX versus PENLAC.
MENTAX vs PENLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal squalene epoxidase, thereby blocking ergosterol biosynthesis and causing accumulation of squalene, leading to fungal cell death.
Ciclopirox, a hydroxypyridone antifungal, inhibits the uptake of essential elements and disrupts fungal cell membrane integrity by chelating polyvalent cations (Fe3+, Al3+). It also inhibits fungal enzymes involved in energy production and detoxification processes.
Butenafine hydrochloride 1% cream: apply to affected area once daily for 2 weeks for tinea pedis; for tinea corporis and tinea cruris, apply once daily for 1 week.
Apply a thin layer to affected nails once daily, preferably at bedtime or 8 hours before washing. Use the provided applicator to apply to the entire nail plate and under the nail tip. Treatment duration is up to 48 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours; clinical significance: supports twice-daily dosing for topical antifungal therapy.
Terminal elimination half-life is 17–21 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe renal failure)
Primarily fecal (biliary) as unchanged drug and metabolites; renal excretion of metabolites accounts for less than 1% of the dose.
Primarily excreted renally as unchanged drug; approximately 90% of absorbed dose recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%)
Category C
Category C
Topical Antifungal
Topical Antifungal